Azelaic acid

Drug Profile

Azelaic acid

Alternative Names: BAY39-6251; Finacea; Finacea Foam; Skinoren Gel

Latest Information Update: 28 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer Dermatology; Bayer HealthCare Pharmaceuticals Inc.
  • Class Antiacnes; Antibacterials; Dicarboxylic acids; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne; Melanosis; Rosacea
  • Discontinued Dermatitis

Most Recent Events

  • 26 Oct 2015 Launched for Rosacea in USA (Topical, Foam)
  • 31 Jul 2015 Adverse events and efficacy data from pivotal phase-III trials in Rosacea (Topical, foam formulation) released by Bayer HealthCare
  • 29 Jul 2015 Registered for Rosacea in USA (Topical, Foam)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top